Rebecca B. Roberts

October 16, 2026

AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.

October 7, 2026

MSA Safety Upgraded Amid New SCBA Launch. MSA Safety received a Buy upgrade from analysts, who suggest the stock may be undervalued following the launch of a new connected Self-Contained Breathing Apparatus. This product development is seen as a key factor in the company's long-term growth potential. The stock currently trades below the average analyst price target, reflecting a valuation gap that some market participants are watching closely.

October 9, 2026

Black Hills Corp. Secures $1.8B Alphabet Deal, Eyes 2026 Earnings. Black Hills Corp. announced a $1.8 billion power‑purchase agreement with Alphabet, which will supply electricity for new AI data centers. The company also set its 2026 third‑quarter earnings release date and a conference call. Analysts at BMO Capital keep an outperform rating and raised the target price to $86. The deal helped lift the stock 8.2 % after the long‑term contract was disclosed.